Abstract
Objective: This investigation delineates the anti-cancer potency of epigallocatechin-3-gallate (EGCG) in an oral cancer mouse model, with a focus on its effect on T-cell activation. Methods: An oral cancer model was established in male Balb/c mice using 4-nitroquinoline 1-oxide (4-NQO). The mice were systematically grouped and administered graded concentrations of EGCG. Key parameters such as body weight, hydration levels, tumor volume, and mass were meticulously tracked. T-cell activity and cytokine expression profiles, focusing on interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α), were quantified using ELISA. A comprehensive statistical evaluation included one-way ANOVA, Tukey’s HSD multiple comparison test, and the Kruskal-Wallis non-parametric assessment. Results: EGCG-administered cohorts exhibited a pronounced reduction in tumor size and mass, with the high-dose group showing the greatest efficacy. ELISA findings corroborated a significant increase in T-cell activity and concomitant upregulation of key cytokines, including IL-2, IFN-γ, and TNF-α (P < 0.05). Conclusion: This investigation confirms the tumor-suppressive efficacy of EGCG in a murine oral squamous cell carcinoma model. The therapeutic effects of EGCG are mediated through T-cell activation and the upregulation of pivotal cytokine expression, highlighting its potential immunomodulatory role in oral cancer treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
